As imatinib showed remarkable effective clinical responses in several cancers [36,40], and as the expression of its targets (c-KIT, PDGFR) has been validated in melanoma, it was also tested in phase II trial but showed limited clinical responses as a single agent, even in tumors with high PTKs expression (Table 2) [41]. Here, KIT is linked to melanoma.